On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study
J Howell, DJ Pinato, R Ramaswami, D Bettinger, T Arizumi, C Ferrari, C Yen, A Gibbin, ME Burlone, G Guaschino, L Sellers, J Black, M Pirisi, M Kudo, R Thimme, J-W Park, R Sharma
Alimentary Pharmacology & Therapeutics | WILEY | Published : 2017
BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mortality despite treatment. While sorafenib has a survival benefit for patients with advanced HCC, clinical response is highly variable. AIM: To determine whether development of sorafenib toxicity is a prognostic marker of survival in HCC. METHODS: In this prospective multicentre cohort study, patients with advanced-stage HCC receiving sorafenib were recruited from five international specialist centres. Demographic and clinical data including development and grade of sorafenib toxicity during treatment, radiological response to sorafenib and survival time (months) were recorded prospectively. R..View full abstract
Awarded by Academy of Medical Sciences (AMS)
Awarded by National Institute for Health Research
JH was supported by a National Medical Research Council of Australia Early Career Fellowship. DJP was supported by the National Institute of Health Research (NIHR). DB was supported by the Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg. This project was funded in part by the Academy of Medical Sciences (AMS, Grant ID SGL013/1021 awarded to DJP).